within Pharmacolibrary.Drugs.ATC.N;

model N03AG02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 1.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Valpromide is an amide derivative of valproic acid, historically used as an anticonvulsant and mood stabilizer. It is the primary amide of valproic acid and is metabolized in vivo to valproic acid. Its use has largely been supplanted by valproic acid and its salts, and valpromide is not widely approved or in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult individuals, as direct published PK models for valpromide are not available. Estimates are based on its rapid conversion to valproic acid and limited primary data.</p><h4>References</h4><ol><li><p>Bialer, M, et al., &amp; Abramsky, O (1984). Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. <i>European journal of clinical pharmacology</i> 27(4) 501–503. DOI:<a href=&quot;https://doi.org/10.1007/BF00549603&quot;>10.1007/BF00549603</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6440792/&quot;>https://pubmed.ncbi.nlm.nih.gov/6440792</a></p></li><li><p>Bialer, M, &amp; Rubinstein, A (1984). Pharmacokinetics of valpromide in dogs after various modes of administration. <i>Biopharmaceutics &amp; drug disposition</i> 5(2) 177–183. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510050211&quot;>10.1002/bdd.2510050211</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6430363/&quot;>https://pubmed.ncbi.nlm.nih.gov/6430363</a></p></li><li><p>Pisani, F, et al., &amp; Bertilsson, L (1988). Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. <i>British journal of clinical pharmacology</i> 25(5) 611–613. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1988.tb03354.x&quot;>10.1111/j.1365-2125.1988.tb03354.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3136790/&quot;>https://pubmed.ncbi.nlm.nih.gov/3136790</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AG02;
